EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof‐of‐concept study

Thomas Bardol iD, Zahra Eslami-S, Doryan Masmoudi, Marie Alexandre, Marie Duboys de Labarre, Angélique Bobrie, Véronique D'Hondt, Séverine Guiu, Keerthi Kurma, Laure Cayrefourcq, William Jacot, Catherine Alix-Panabières

Cancer Medicine · 2024

DOI: 10.1002/cam4.6843 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Thomas Bardol und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Rare Circulating Human Cells-University Medical Center of Montpellier, Montpellier, France. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Axl Receptor Tyrosine Kinase, Receptor Protein-Tyrosine Kinases, Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MUSE grant "KIM Biomarkers and therapy", University of Montpellier.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

For several years, the AXL tyrosine kinase receptor, a member of the Tyro3‐Axl‐Mer (TAM) family, has been considered a new strategic target in oncology. AXL overexpression is common in solid tumors and is associated with poor prognosis. In this context, the detection of a subset of circulating tumor cells (CTCs) that express AXL (AXL + CTCs) could be clinically relevant.

Methods

Immunostaining was performed to assess AXL expression in human breast cancer cell lines. The optimal conditions were established using flow cytometry. Spiking experiments were carried out to optimize the parameters of the CellSearch ® system detection test. CTC enumeration and AXL expression were evaluated in patients with metastatic breast cancer (mBC) before treatment initiation.

Results

An innovative AXL + CTC detection assay to be used with the CellSearch ® system was developed. In a prospective longitudinal clinical trial, blood samples from 60 patients with untreated mBC were analyzed to detect AXL + CTCs with this new assay. CTCs were detected in 35/60 patients (58.3%) and AXL + CTCs were identified in 7 of these 35 patients (11.7% of all patients).

Conclusion

This newly established AXL + CTC assay is a promising tool that can be used for liquid biopsy in future clinical trials to stratify and monitor patients with cancer receiving anti‐AXL therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Cells, CirculatingAxl Receptor Tyrosine KinaseReceptor Protein-Tyrosine KinasesBreast NeoplasmsProto-Oncogene ProteinsHumansFemaleMiddle AgedCell Line, TumorAgedBiomarkers, TumorProof of Concept StudyNeoplasm MetastasisProspective StudiesAdult

Stichwörter der Autor:innen

AXLcirculating biomarkercirculating tumor cellsliquid biopsymetastatic breast cancer

Substanzen

Axl Receptor Tyrosine KinaseReceptor Protein-Tyrosine KinasesProto-Oncogene ProteinsAXL protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Laboratory of Rare Circulating Human Cells-University Medical Center of Montpellier, Montpellier, France.
  • CREEC/CANECEV, MIVEGEC (CREES), Université de Montpellier, CNRS, IRD, Montpellier, France.
  • European Liquid Biopsy Society (ELBS), Hamburg, Germany.
  • Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.
  • Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier University, Montpellier, France.

ORCID-Profile: Thomas Bardol

Förderung

  • MUSE grant "KIM Biomarkers and therapy", University of Montpellier

Zitieren

APA

Bardol, T., Eslami-S, Z., Masmoudi, D., Alexandre, M., Duboys de Labarre, M., Bobrie, A., D'Hondt, V., Guiu, S., Kurma, K., Cayrefourcq, L., Jacot, W., & Alix-Panabières, C. (2024). First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof‐of‐concept study. Cancer Medicine. https://doi.org/10.1002/cam4.6843

Vancouver

Bardol T, Eslami-S Z, Masmoudi D, Alexandre M, Duboys de Labarre M, Bobrie A, et al. First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof‐of‐concept study. Cancer Medicine. 2024. doi:10.1002/cam4.6843

BibTeX
@article{Bardol2024,
  author = {Bardol, Thomas and Eslami-S, Zahra and Masmoudi, Doryan and Alexandre, Marie and Duboys de Labarre, Marie and Bobrie, Angélique and D'Hondt, Véronique and Guiu, Séverine and Kurma, Keerthi and Cayrefourcq, Laure and Jacot, William and Alix-Panabières, Catherine},
  title = {First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof‐of‐concept study},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6843}
}
Kostenlos starten →